Amid the topmost stocks in today’s market is Edwards Lifesciences Corp. (NYSE:EW). Edwards Lifesciences Corp. had a market cap of 17086.39, indicating that it has a good hold on the market value of the shares outstanding. The current market cap of Edwards Lifesciences Corp. exhibits the basic determinant of asset allocation and risk-return parameters for its stocks.
The P/E of Edwards Lifesciences Corp. is currently valued at 37.54 allowing its investors to analyze the company’s stock valuation and its shares relative to the income of the company that it makes. With the constructive P/E value of Edwards Lifesciences Corp., the investors are able to forecast the positive earnings growth of the company.
The forward P/E of Edwards Lifesciences Corp. is at 33.14 signifying the uses of estimated net earnings over the next 12 months. Investors will be getting a good grip in comparing the current earnings of the company to estimated future earnings.
With its low price-to-sales ratio of 7, the company is evidently a better investment since the investors are paying a lower amount for each unit of sales. However, the company sales do not necessarily expose the entire picture, as it might be unprofitable with a low P/S ratio.
The price-to-book ratio of 7.04 for Edwards Lifesciences Corp. (NYSE:EW) implies that investors are highly hopeful for the organization to create more value from the given set of assets. The market value of the firm’s assets are considerably higher in contrast to their accounting value. The current P/B amount of Edwards Lifesciences Corp. best indicates the value approach in differentiating good from the bad. The ratio also provides a clue to how much investors are paying for what would be left if the company went bankrupt immediately.
The target payout ratio for Edwards Lifesciences Corp. is currently measuring at 0.00%, outlining what size the company’s dividends should be. It also demonstrates a stable dividend policy for Edwards Lifesciences Corp. connected to the long-run, with viable earnings.
The EPS for Edwards Lifesciences Corp. is valued at 2.11 with an EPS growth this year at 118.70%. The company’s EPS growth for the following year is valued at 5.94%, indicating an EPS value of 31.00% for the past 5 years, and an EPS value of 15.85% for the coming five years.
Edwards Lifesciences Corp.’s sales for the past 5 years rolls at 11.90%, exhibiting an EPS growth from quarter-to-quarter at 22.70%. The sales growth of the company is 1.30% at the moment, indicating the average sales volume of the company’s products and services that have typically improved year-to-year.
Company’s existing stock price is at 79.27 with a change in price of 0.08%. As of now, the target price for the company is measuring at 88.68. Edwards Lifesciences Corp.’s ROA is rolling at 12.80%, following the ROI of 29.10%. Quick and current ratio is valued at 3.4 and 4 respectively.